Mode of acquisition of hepatitis C virus infection in patients from southern Hunan province hospitalized with chronic hepatitis C

Zhou YouQian; Yin FengMing; Feng JingHua

Issue 6

Jun. 2012

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2012 > 28(6): 443-445

PDF( 1070 KB)

Mode of acquisition of hepatitis C virus infection in patients from southern Hunan province hospitalized with chronic hepatitis C

Published Date: 2012-06-20

Abstract

Abstract

Objective To investigate the characteristics of hepatitis C virus (HCV) infection mode of acquisition in hospitalized patients with chronic hepatitis C (CHC) , and to provide a reference for designing preventative measures against CHC.Methods The electronic medical records of patients diagnosed with HCV and hospitalized between January 2005 and December 2011 were retrospectively identified and downloaded for analysis.Measurements of anti-HCV, by chemiluminescence assay, and serum HCV RNA, by real-time quantitative RT-PCR.Data on the department of treatment, clinical and demographic features, and lifestyle risk factors were extracted.Results The most frequent clinical feature of patients treated in the Nephrology Department was hemodialysis (80.0%) , in the Obstetrics and Gynecology Department was surgery (64.7%) , and in the Infectious Diseases Department was blood transfusion (39.0%) followed closely by intravenous drug abuse (28.6%) .In the other departments (collectively pooled) , blood transfusion (40.7%) and intravenous drug abuse (37.0%) were the most frequent.The differences in rates of the most frequent clinical features from among the four groups of hospital departments were statistically significant (P<0.01) .The most frequently reported cause of infection for patients aged 40 years or younger was intravenous drug use (38.2%) , while patients over 40 were mainly infected by blood transfusion (49.3%) ;for both cuases, the differences in rates between the two age groups were statistically significant (P<0.01) .Male patients were mainly infected by intravenous drug use (35.0%) and blood transfusion (32.5%) , while female patients were mainly infected by surgery (32.7%) and blood transfusion (26.9%) ;for these four causes, the differences in rates between the two sex groups were statistically significant (P<0.01) .Conclusion The mode of HCV infection among the population stratified by age and sex shows clear diversification.Intravenous drug abuse appears to be an important infection route for younger individuals and males.
- hepatitis C,
- chronic

FullText(HTML)

References(13)

References

[1]Ghany MG, Strader DB, Thomas DL, et al.Diagnosis, manage-ment, and treatment of hepatitis C:an update[J].Hepatology, 2009, 49 (4) :1335-1374.

[2]魏欣, 谢玉梅, 陈琳, 等.丙型肝炎肝硬化的“分级”及聚乙二醇干扰素α-2a联合利巴韦林的抗病毒治疗[J].临床肝胆病杂志, 2011, 27 (1) :89-92.

[3]Esteban JI, Sauleda S, Quer J.The changing epidemiology of hepa-titis C virus infection in Europe[J].J Hepatol, 2008, 48 (1) :148-162.

[4]Zhou YQ, Wang XH, Mao Q, et al.Changes in modes of hepatitisC infection acquisition and genotypes in southwest China[J].J ClinVirol, 2009, 46 (3) :230-233.

[5]张建华, 钟怀印, 薛承岩.不同人群丙型肝炎病毒传播途径分析[J].临床肝胆病杂志, 2007, 23 (4) :253-254.

[6]何强, 康志敏, 王芳, 等.实施感染防治措施对血液透析乙肝及丙肝病毒感染控制的效果观察[J].实用医院临床杂志, 2010, 7 (4) :49-51.

[7]胡晓武, 丁必芝.丙型肝炎流行病学及临床特征调查分析[J].实用肝脏病杂, 2010, 13 (3) :188-189.

[8]Andriulli A, Mangla A, Iacobellis A, et al.Meta-analysis:theoutcome of anti-viral therapy in HCV genotype 2 and genotype 3infected patients with chronic hepatitis[J].Aliment Pharmacol T-her, 2008, 28 (4) , 397-404.

[9]Sarrazin C, Schwendy S, Mller B, et al.Improved Responses toPegylated Interferon alfa-2b and Ribavirin by IndividualizingTreatment for 24-72 Weeks[J].Gastroenterology, 2011, 141 (5) :1656-1664.

[10]李巧于, 郭垫, 曾菲, 等.α-1b干扰素联合利巴韦林治疗丙型肝炎临床观察[J].实用肝脏病杂志, 2010, 13 (4) :302.

[11]陈文, 王鲁文, 袁念芳, 等.小剂量α-干扰素治疗失代偿期丙型肝炎肝硬化的疗效观察[J].实用肝脏病杂志, 2008, 11 (3) :174-175.

[12]Nguyen-Khac E, Capron D, Castelain S, et al.Personalized ther-apy for chronic viral hepatitis C in the naive patient:How can weoptimize treatment duration as a function of viral genotype?[J].Eur J Intern Med, 2007, 18 (7) :510-515.

[13]Chlabicz S, Flisiak R, Kowalczuk O, et al.Changing HCV geno-types distribution in Poland-relation to source and time of infection[J].J Clin Virol, 2008, 42 (2) :156-159.

Relative Articles

[1]	Jinni HUANG, Jianning JIANG, Dandan LIANG, Shiyu LONG, Guozhen DONG, Man SU, Jijiao LI, Chunling TENG, Ping ZHANG, Minghua SU. Epidemiological features and antiviral response of genotype 6 chronic hepatitis C[J]. Journal of Clinical Hepatology, 2022, 38(4): 793-797. doi: 10.3969/j.issn.1001-5256.2022.04.011
[2]	Shan SHAN, Lianhui ZHAO, Hong MA, Xiaojuan OU, Hong YOU, Jidong JIA. Definition, etiology, and epidemiology of liver cirrhosis[J]. Journal of Clinical Hepatology, 2021, 37(1): 14-16. doi: 10.3969/j.issn.1001-5256.2021.01.003
[3]	Xu JinFeng, Zhang XiaoHui, Liu YaLi, Zhang Jing. Influencing factors for hemolytic anemia in patients with chronic hepatitis C treated by ribavirin combined with pegylated interferon-α[J]. Journal of Clinical Hepatology, 2019, 35(2): 319-322. doi: 10.3969/j.issn.1001-5256.2019.02.015
[4]	Bu Fan, Hou JunXing, Yu YueCheng. An excerpt of the management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver[J]. Journal of Clinical Hepatology, 2018, 34(8): 1644-1648. doi: 10.3969/j.issn.1001-5256.2018.08.010
[5]	Wang XiaoPing, Tang ShanHong, Jing Dan, Wu XiaoLing, Ceng WeiZheng, Jiang MingDe. An excerpt of American Gastroenterological Association Institute Clinical Practice Update-Expert Review: care of patients who have achieved a sustained virologic response after antiviral therapy for chronic hepatitis C infection（2017）[J]. Journal of Clinical Hepatology, 2017, 33(6): 1046-1050. doi: 10.3969/j.issn.1001-5256.2017.06.005
[6]	Yang LuXuan, Zhang Xin. Research advances in risk factors for hepatocellular carcinoma in chronic hepatitis C patients with sustained virologic response[J]. Journal of Clinical Hepatology, 2017, 33(3): 543-547. doi: 10.3969/j.issn.1001-5256.2017.03.033
[7]	Zhang YueRong, Zhou Ning, Li XiangLin, Wu LiYang, Wei ShiFang, Zhang YaoDi, Zhang YuePing. Causes and countermeasures for relapse after drug withdrawal in patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2015, 31(9): 1434-1438. doi: 10.3969/j.issn.1001-5256.2015.09.017
[8]	Jia Ying, Li XiaoGuang, Li Lu, Liang JingJin, Kang YongFeng, Lin Fei, Deng ZhongHua, Wang Wei, Zhang BiYing, Xu Jie. Quality of life and its influential factors in outpatients with chronic hepatitis B or C[J]. Journal of Clinical Hepatology, 2015, 31(10): 1695-1698. doi: 10.3969/j.issn.1001-5256.2015.10.034
[9]	Jiang Ni, Mao XiaoRong, Peng XueBin, Li YueYue, Chen QiMing, Chen QingFeng. Analysis of factors influencing hepatitis C with thyroid dysfunction in Chinese patients[J]. Journal of Clinical Hepatology, 2015, 31(8): 1266-1270. doi: 10.3969/j.issn.1001-5256.2015.08.020
[10]	Zhang DanDan, Ye PeiYan, Huang YuXian, Xu GuoGuang, Zhang Yi, Li XinYan, Chen Liang. Analysis of predictive factors for rapid virologic response in treating patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2014, 30(12): 1310-1314. doi: 10.3969/j.issn.1001-5256.2014.12.019
[11]	Jiang ShuiQing, Wang Jian, Hu XiaoBin, Li YuZhi, Lu YouJie, Tong Rui, Tong Min. Epidemiology and treatment strategies for hepatitis C in the northern region of Anhui province[J]. Journal of Clinical Hepatology, 2012, 28(12): 937-940.
[12]	Zhou YouQian, Yin FengMing, Feng JingHua. Regularity of relapse after antiviral treatment in patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2012, 28(8): 609-611.
[13]	Hu XiaoLi, Zhao HongWei, Wu XiaoYan, Niu JunQi. Prevalence of hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2012, 28(6): 413-416+421.
[14]	Yu Hui. Advances in epidemiology, diagnosis and treatment of hepatitis B in children[J]. Journal of Clinical Hepatology, 2011, 27(7): 687-689.
[15]	Qu SiMai, Zhang Lin. Research advancement of antiviral treatment for chronic hepatitis C[J]. Journal of Clinical Hepatology, 2011, 27(12): 1331-1335.
[16]	Jiang XueQiang, Zou XiaoJing, Tian DeYing. Virological response of chronic hepatitis C treated with peg-interferon α-2a and Ribavirin[J]. Journal of Clinical Hepatology, 2011, 27(4): 417-419.
[17]	Liu XueMei, Meng QingHua. A case of antiviral treatment for type I diabetes patient with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2011, 27(6): 653+65.
[18]	Zhou WenHong, Ying Hao. Analysis of the factors influencing the prognosis of chronic severe hepatitis B[J]. Journal of Clinical Hepatology, 2007, 23(1): 26-27.
[19]	Chen Yan, Tian DeYing, Xia NingShao. Epidemiology and the genotypes of HEV isolated from patients with hepatitis E in Wuhan[J]. Journal of Clinical Hepatology, 2006, 22(1): 36-38.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2942) PDF downloads(638)

Mode of acquisition of hepatitis C virus infection in patients from southern Hunan province hospitalized with chronic hepatitis C

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Mode of acquisition of hepatitis C virus infection in patients from southern Hunan province hospitalized with chronic hepatitis C

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content